Alluvi, known as BI 4744, offers a promising breakthrough in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable results in patient studies, arguably https://alluvipeptides117875.wikievia.com/user